aflibercept
Cold Chain RequiredFDA Approved, EMA Approved
Description
Aflibercept is a recombinant fusion protein that acts as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF). It is administered as an intravitreal injection for the treatment of various retinal diseases including age-related macular degeneration. The drug provides sustained VEGF inhibition to reduce retinal fluid and improve vision.
Indications & Therapeutic Use
neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema following retinal vein occlusion
Linked Diseases:
macular degeneration
D008268
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
aflibercept
| Generic Name | aflibercept |
| Brands | 1 brand available |
| Active Ingredient | aflibercept |
| Drug Class | neovascular age-related macular degeneration |
| Manufacturer | Regeneron Pharmaceuticals |
| Dosage Forms | intravitreal injection, 40 mg/mL solution |
| Medical Code | S01LA05 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00509795 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes